Skip to main content

Table 1 Study Inclusion and Exclusion Criteria

From: Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

Criterion Inclusion Exclusion
Patient population Adults (> 18 years old) with bipolar depression where at least 50% of the population were diagnosed with bipolar I disorder •< 50% bipolar I disorder
•< 18 years old
Interventions Atypical antipsychotic monotherapy:
•Cariprazine1
•Lurasidone
•Quetiapine
•Olanzapine
•Aripiprazole
•Asenapine
•Risperidone
•Ziprasidone
•Brexpiprazole1
•Lumateperone1
•All other atypical antipsychotic monotherapies assessed for the treatment of bipolar I depression2
•Any treatments other than those listed in the inclusion criteria
•Any treatments listed in inclusion criteria if administered as adjunctive therapy
Comparators Any of the above listed interventions or placebo Comparators other than those listed in the inclusion criteria
Outcomes Studies reporting at least one of the following outcomes:
•Change from baseline in MADRS
•Change from baseline in CGI-BP-S
•Response (defined as ≥50% improvement inMADRS)
•Remission (defined as MADRS score ≤ 12 and ≤ 10at endpoint)
•≥ 7% weight gain
•Change from baseline in weight
•Change from baseline in glucose level
•Change from baseline in low-density lipoprotein (LDL)
•Change from baseline in total cholesterol
•Change from baseline in triglycerides
•Change from baseline in prolactin
•Akathisia
•Extrapyramidal symptoms
•Somnolence
•All-cause discontinuation
•Discontinuation due to lack of efficacy
•Discontinuation due to adverse events
•Switch to mania3
Studies not reporting least one of the outcomes included in the inclusion criteria.
Study design Randomized controlled trials •Non-randomized controlled trials
•Observational studies
•Case studies
•Pharmacology studies
  1. Abbreviations: CGI-BP-S Clinical Global Impressions – Bipolar Disorder – Severity, MADRS Montgomery–Åsberg Depression Rating Scale. 1treatments were added to the update since they were approved after the original search in 2015. 2Other atypical antipsychotic monotherapies were allowed in the update to ensure any new treatments were not excluded. 3Switch to mania was added post-hoc